TTRX Stock Summary and Trading Ideas (Turn Therapeutics | NASDAQ:TTRX)

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Turn Therapeutics trades on the NASDAQ stock market under the symbol TTRX.

As of November 13, 2026, TTRX stock price declined to $9.35 with 89,350 million shares trading.

TTRX has a beta of 1.07, meaning it tends to be more sensitive to market movements. TTRX has a correlation of 0.02 to the broad based SPY ETF.

TTRX has a market cap of $283.79 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that TTRX belongs to (by Net Assets): VTI, VXF, IWC, BUSM.

TTRX has outperformed the market in the last year with a return of +112.4%, while the SPY ETF gained +11.5%. However, in the most recent history, TTRX shares have underperformed the stock market with its stock returning -11.3% in the last 3 month period and -12.8% for the last 2 week period, while SPY has returned -2.1% and -1.9%, respectively.

TTRX support price is $9.43 and resistance is $10.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TTRX shares will trade within this expected range on the day.